Cytek Biosciences, Inc.
CTKB
$3.96
$0.195.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -557.63% | -1,005.30% | -26.18% | 63.53% | 2.23% |
| Total Depreciation and Amortization | 9.07% | 14.16% | 14.73% | 15.09% | 10.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 320.90% | 314.31% | -74.27% | -54.19% | -37.41% |
| Change in Net Operating Assets | -86.79% | -162.15% | -172.74% | -99.65% | 172.00% |
| Cash from Operations | -134.26% | -118.46% | -105.83% | -1.51% | 233.81% |
| Capital Expenditure | -41.92% | -15.86% | 3.73% | 2.67% | 19.17% |
| Sale of Property, Plant, and Equipment | -29.91% | -12.50% | 155.67% | 252.63% | -- |
| Cash Acquisitions | -- | -- | -99.58% | -98.73% | -98.73% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 66.72% | 117.60% | -442.69% | -211.77% | -186.03% |
| Cash from Investing | 61.02% | 112.19% | -640.41% | -225.92% | -197.89% |
| Total Debt Issued | 186.45% | 33.51% | 397.92% | 249.75% | 149.43% |
| Total Debt Repaid | -111.57% | -751.89% | -248.39% | -248.74% | -246.95% |
| Issuance of Common Stock | -35.35% | -45.79% | -42.90% | -47.54% | -37.89% |
| Repurchase of Common Stock | 84.05% | 28.97% | 54.64% | 25.41% | 26.62% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 107.23% | 15.11% | 65.50% | 29.09% | 27.91% |
| Foreign Exchange rate Adjustments | 23.24% | -97.59% | -90.19% | -134.16% | 20.07% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 59.87% | 88.54% | -5,105.35% | -320.92% | -300.95% |